Repository COMVIVIR .xlsx

This research evaluated the effect of Maraviroc and/or Favipiravir plus systemic steroids versus systemic steroids only on the viral load of adults with severe COVID-19: clinical trials .COVID-19 has created the need to evaluate drugs such as favipiravir and inhibitor of RNA-dependent RNA-polymerase and Maraviroc, and antiretroviral that antagonizes the chemokine receptor CCR5, which could affect the modulation of inflammation and viral replication in the treatment of COVID-19. We included sixteen patients with severe COVID-19 were evaluated in three treatment arms: 1) SS only, 2) Steroid systemic plus one test drug Maraviroc or Favipiravir and 3) Steroid systemic plus both test drugs (maraviroc and favipiravir). The viral load was determined for N,E, and RdRp viral genes.A significant decrease in viral load was observed in the three treatment groups, with a larger effect size in the group that combined Steroid sistemic with both test drugs. The E, N, and RdRp genes with Cohen's d, were 120,123, aand 50% respectively.<br>